secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001193125-25-144174
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating
--------------------------------------------------------------------------------

- Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).
- CD3+ IELs declined by 1.5 on FB102 vs increase of 13.3 for placebo (p=0.0035).
- Gluten challenge GI symptom events per subject: 4.0 for FB102 vs 6.9 for placebo (42% benefit).
- No grade 3+ SAEs in FB102 arm; all TEAEs mild; no dropouts.
- Phase 2 celiac trial initiating; topline readout expected in 2026; vitiligo readout H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525144174/0001193125-25-144174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525144174/d874957d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-144174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer